Clinical Trial Update: Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing dabrafenib plus trametinib versus vemurafenib alone in unresectable or metastatic BRAF V600E/K cutaneous melanoma has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2014-12-04